NASDAQ:BLTE Belite Bio Q2 2026 Earnings Report $167.26 +4.21 (+2.58%) As of 04:00 PM Eastern ProfileEarnings HistoryForecast Belite Bio EPS ResultsActual EPSN/AConsensus EPS -$0.73Beat/MissN/AOne Year Ago EPSN/ABelite Bio Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ABelite Bio Announcement DetailsQuarterQ2 2026Date8/13/2026TimeAfter Market ClosesConference Call DateThursday, August 13, 2026Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile Belite Bio Earnings HeadlinesBelite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Receives Consensus Rating of "Moderate Buy" from BrokeragesAugust 9 at 2:14 AM | americanbankingnews.comBelite Bio to Host Webcast on August 13, 2026, to Discuss Second Quarter 2026 Financial ResultsAugust 7 at 1:45 AM | markets.businessinsider.com$8B is moving in... are you?Venture capital investment in US crypto companies hit $7.9 billion last year, up 44 percent from the year before, as the smartest institutional money doubles down on blockchain infrastructure. This isn't speculative crypto trading. It's the payment rails and settlement systems moving money faster and cheaper. BlackRock, JPMorgan, and Fidelity are already accumulating the single digital asset positioned at the center of a $382 trillion shift in financial assets by April 2027.August 10 at 1:00 AM | Awesomely (Ad)Belite Bio: The Oral Route Is The Real Competitive MoatJuly 29, 2026 | seekingalpha.comBelite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt ...July 20, 2026 | markets.businessinsider.comBelite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1July 20, 2026 | globenewswire.comSee More Belite Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Belite Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Belite Bio and other key companies, straight to your email. Email Address About Belite BioBelite Bio (NASDAQ:BLTE), Inc. (NASDAQ: BLTE) is a clinical-stage biotechnology company focused on discovering and developing small molecule therapeutics for metabolic and inflammatory diseases. Leveraging a proprietary drug-discovery platform, the company aims to address conditions such as nonalcoholic steatohepatitis (NASH) and obesity by targeting pathways involved in fibrosis, inflammation and metabolic regulation. Belite Bio’s pipeline includes multiple candidates in preclinical and early clinical development stages. The company has established research collaborations with academic institutions and contract research organizations to advance its lead programs through regulatory milestones, emphasizing optimization of safety, efficacy and pharmacokinetic profiles to support future clinical trials. Based in the United States, Belite Bio is led by a management team with extensive experience in biotechnology, drug development and regulatory affairs. The company’s strategic vision is to deliver innovative therapies for metabolic disorders with significant unmet medical needs and to pursue global clinical development to reach diverse patient populations. View Belite Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles SoundHound AI Sends a Loud Signal After Its Q2 Earnings Beat5 Stocks the Market Rewarded After Strong Earnings ResultsQuantum Earnings Week: Winners and Losers Are Finally EmergingMarketBeat Week in Review – 08/03 - 08/07Take-Two’s Q1 Results Leave GTA 6 Bulls Stuck in the Fog of WarCloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in FocusIs Monster Beverage’s Best-Case Scenario Already Priced Into the Stock? Upcoming Earnings SEA (8/11/2026)Cardinal Health (8/11/2026)Lumentum (8/11/2026)Cisco Systems (8/12/2026)Brookfield (8/13/2026)NU (8/13/2026)Applied Materials (8/13/2026)BHP Group (8/17/2026)Palo Alto Networks (8/17/2026)Home Depot (8/18/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
